SEI Investments’s Crescent Biopharma CBIO Stock Holding History

SEI Investments’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200	Closed	-$60K	–	2576
2021 Q1	$60K	Hold	200	–	–	﹤0.01%	2456
2020 Q4	$75K	Hold	200	–	–	﹤0.01%	2430
2020 Q3	$61K	Hold	200	–	–	﹤0.01%	2365
2020 Q2	$75K	Buy	+200	New	+$56.6K	﹤0.01%	2342

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SEI Investments's CBIO Position: Q2 2021 in Review

SEI Investments sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 200 shares — an estimated $60K sold.

SEI Investments first reported a position in CBIO in Q2 2020 and held it in 4 quarters. The position peaked at $75K in Q4 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

SEI Investments reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
SEI Investments sold 200 Crescent Biopharma shares in Q2 2021, an estimated $60K.
SEI Investments first reported a position in Crescent Biopharma in Q2 2020 and held it in 4 quarters.
SEI Investments's Crescent Biopharma position peaked at $75K in Q4 2020.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on SEI Investments's 13F filing for Q2 2021, filed 6 Aug 2021.